Influence of baseline variables on transplantation outcome: clinical end points and corresponding Cox models (backward exclusion, P > .02)
Clinical end point . | Baseline variable . | Hazard ratio . | 95% Confidence interval . | P . |
|---|---|---|---|---|
| Overall survival | Disease stage | 3.31 | 2.3-4.6 | <.0001 |
| Patient age | 1.03* | 1.01-1.05 | .002 | |
| Interval Dg → TX | 1.09* | 1.00-1.2 | .07 | |
| Donor age | 1.01* | 0.99-1.02 | .15 | |
| Treatment-related mortality | Disease stage | 3.45 | 2.3-5.0 | <.0001 |
| Patient age | 1.04* | 1.02-1.06 | <.001 | |
| Donor age | 1.02* | 1.00-1.03 | .04 | |
| Acute graft-vs-host disease | Donor MFD | 2.18 | 1.3-3.5 | <.0001 |
| Donor MUD | 1.72 | 1.05-2.79 | .03 | |
| Patient age | 1.02* | 1.00-1.05 | .02 | |
| Donor age | 1.01* | 0.99-1.03 | .15 | |
| Disease stage | 1.31 | 0.98-1.99 | .14 | |
| Relapse | Disease stage | 3.15 | 1.7-5.6 | <.0001 |
| Donor MUD | 0.42 | 0.2-0.8 | .01 | |
| Donor MFD | 0.51 | 0.2-1.0 | .05 | |
| Graft source | 1.91 | 1.0-3.5 | .03 | |
| Sex mismatch | 0.42 | 0.2-0.9 | .12 |
Clinical end point . | Baseline variable . | Hazard ratio . | 95% Confidence interval . | P . |
|---|---|---|---|---|
| Overall survival | Disease stage | 3.31 | 2.3-4.6 | <.0001 |
| Patient age | 1.03* | 1.01-1.05 | .002 | |
| Interval Dg → TX | 1.09* | 1.00-1.2 | .07 | |
| Donor age | 1.01* | 0.99-1.02 | .15 | |
| Treatment-related mortality | Disease stage | 3.45 | 2.3-5.0 | <.0001 |
| Patient age | 1.04* | 1.02-1.06 | <.001 | |
| Donor age | 1.02* | 1.00-1.03 | .04 | |
| Acute graft-vs-host disease | Donor MFD | 2.18 | 1.3-3.5 | <.0001 |
| Donor MUD | 1.72 | 1.05-2.79 | .03 | |
| Patient age | 1.02* | 1.00-1.05 | .02 | |
| Donor age | 1.01* | 0.99-1.03 | .15 | |
| Disease stage | 1.31 | 0.98-1.99 | .14 | |
| Relapse | Disease stage | 3.15 | 1.7-5.6 | <.0001 |
| Donor MUD | 0.42 | 0.2-0.8 | .01 | |
| Donor MFD | 0.51 | 0.2-1.0 | .05 | |
| Graft source | 1.91 | 1.0-3.5 | .03 | |
| Sex mismatch | 0.42 | 0.2-0.9 | .12 |
Disease stage indicates early = 0, advanced = 1; patient age, the patient age at transplantation (years); interval Dg → TX, time interval between diagnosis and transplantation (years); donor age, donor age at transplantation (years); donor MFD, use of a matched family donor = 1 versus other type of donor = 0; donor MUD, use of a matched unrelated donor = 1 versus other type of donor = 0; graft source, bone marrow = 1, peripheral blood = 0; and sex mismatch, female donor for male patient = 1 versus other constellation = 0
Note that the given hazard ratios are calculated on a per-year basis